Alpha Cognition Inc (ACOG) Stock Price, Quote & News

Company Profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranas...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 344 4375

Website: www.alphacognition.com

Address:

1452 Hughes Street, Suite 200, Grapevine, United States

Squicc Sep. 11 at 5:00 PM

$ACOG

0 · Reply

FlowerInTheCellar Sep. 10 at 7:29 PM

$ACOG https://www.businesswire.com/news/home/20260909061312/en/Alpha-Cognition-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4 -Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4— *Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on September 8, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 25,000 shares of common stock to a new non-executive employee under the Company’s 2026 Inducement Grant Plan.*

0 · Reply

jheerdink Sep. 7 at 7:32 PM

$ACOG "Alpha Cognition Inc. has moved meaningfully beyond the familiar small-cap biotech ritual of promising future potential. Since CEO Michael McFadden’s January 15, 2026 Tribe Public luncheon presentation during the J.P. Morgan Healthcare Conference week in San Francisco, the company has paired its Alzheimer’s commercial launch https://vistapglobal.com/alpha-cognitions-commercial-alzheimers-story-is-getting-harder-to-ignore-acog/

1 · Reply

FlowerInTheCellar Sep. 1 at 9:08 PM

$ACOG https://www.businesswire.com/news/home/20260901907859/en/Alpha-Cognition-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4 - Alpha today announced that on August 31st, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 20,000 shares of common stock to a new non-executive employee under the Company’s 2026 Inducement Grant Plan. The 2026 Inducement Grant Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of the Company. The Compensation Committee approved the stock options as an inducement material to such new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).……..-

0 · Reply

Itinerant Sep. 1 at 4:40 PM

$ACOG Does anyone have access to the ACOG scripts weekly?

1 · Reply

Itinerant Aug. 29 at 4:25 PM

$ACOG I am now long this stock. However, I do not believe, as some here appear to believe that this is a wonderful, leading AD drug. In my view, it is a modest symptomatic relief drug that loses perceptible efficacy after some relatively short interval of time. That is now to say that the drug cannot do well. The success of the drug relies upon high volume, low cost distribution. That is possible with the hoped for approval in China. The Long Term Care channel can consume an enormous amount of this drug when China is included. Nevertheless, the drug will fail in the not too distant future because it is not disease modifying. The present market cap of the company is not a screaming bargain. The cap relies upon a China approval. JMO

2 · Reply

Itinerant Aug. 27 at 4:05 PM

$ACOG Curiously, does someone know what exactly the label says?

1 · Reply

endrow Aug. 24 at 7:28 PM

$ACOG https://www.marketbeat.com/instant-alerts/alpha-cognition-nasdaqacog-director-purchases-10000-shares-2026-08-24/

0 · Reply

History101 Aug. 24 at 3:24 AM

$ACOG 406 watching Sun 8/23/2026

0 · Reply

GeorgeJonesFan_In_Boston Aug. 22 at 3:29 PM

$ACOG Schwab still won’t let you buy online, only through phone calls. It’s been months.

1 · Reply

Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-20T08:15:23.000Z - 24 days ago

Alpha Cognition initiated with a Buy at B. Riley

2026-08-20T01:15:13.000Z - 24 days ago

Alpha Cognition initiated with a Buy at B. Riley

2026-08-17T15:25:07.000Z - 27 days ago

Alpha Cognition price target raised to $20 from $18 at H.C. Wainwright

Aug 17, 2026, 10:43 AM EDT - 27 days ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26

2026-08-16T14:10:29.000Z - 4 weeks ago

Alpha Cognition reports Q2 EPS (40c), consensus (39c)

2026-08-16T13:11:37.000Z - 4 weeks ago

Alpha Cognition price target raised to $17 from $14 at Craig-Hallum

Aug 13, 2026, 4:30 PM EDT - 4 weeks ago

Alpha Cognition Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 4 weeks ago

Alpha Cognition Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 4 weeks ago

Alpha Cognition Quarterly report: Q2 2026

Aug 13, 2026, 4:05 PM EDT - 4 weeks ago

Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

Alpha Cognition Slides: Corporate presentation

2026-08-03T14:10:11.000Z - 5 weeks ago

Alpha Cognition Inc trading resumes

2026-08-03T14:06:23.000Z - 5 weeks ago

Alpha Cognition Inc trading halted, volatility trading pause

Aug 3, 2026, 8:30 AM EDT - 5 weeks ago

Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update

2026-07-29T12:35:47.000Z - 6 weeks ago

Alpha Cognition announces EPO granted patent covering benzgalantamine

Jul 29, 2026, 8:30 AM EDT - 6 weeks ago

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer's Disease

Jul 10, 2026, 8:30 AM EDT - 2 months ago

Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit

2026-07-10T10:15:18.000Z - 2 months ago

Alpha Cognition initiated with an Outperform at Raymond James

2026-06-23T17:04:49.000Z - 2 months ago

Alpha Cognition appoints Robert Wills as chairman of the board

Jun 23, 2026, 8:30 AM EDT - 2 months ago

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

2026-06-16T12:39:44.000Z - 2 months ago

Alpha Cognition announces enrollment of first patient in Resolve

Jun 16, 2026, 8:30 AM EDT - 2 months ago

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease

2026-06-09T12:05:39.000Z - 3 months ago

Alpha Cognition reports results from Beacon real-world study of Zunevyl

Jun 9, 2026, 8:00 AM EDT - 3 months ago

Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's Disease

2026-05-29T14:26:06.000Z - 3 months ago

Maxim starts Alpha Cognition at Buy, sees ‘significant’ market opportunity

2026-05-29T12:00:51.000Z - 3 months ago

Alpha Cognition initiated with a Buy at Maxim

May 16, 2026, 7:00 AM EDT - 4 months ago

Alpha Cognition Slides: Corporate presentation

2026-05-14T20:57:06.000Z - 4 months ago

Alpha Cognition reports Q1 EPS (32c) vs (11c) last year

May 14, 2026, 4:30 PM EDT - 4 months ago

Alpha Cognition Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 4 months ago

Alpha Cognition Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 4 months ago

Alpha Cognition Earnings release: Q1 2026

May 14, 2026, 4:15 PM EDT - 4 months ago

Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Alpha Cognition Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Alpha Cognition Proxy statement: Proxy filing

Apr 28, 2026, 4:30 PM EDT - 4 months ago

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

Apr 20, 2026, 5:00 PM EDT - 4 months ago

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

2026-04-17T12:11:39.000Z - 4 months ago

Craig-Hallum bullish on Alpha Cognition, initiates with a Buy

2026-04-17T11:38:54.000Z - 4 months ago

Alpha Cognition initiated with a Buy at Craig-Hallum

2026-04-01T20:37:03.000Z - 5 months ago

Alpha Cognition granted U.S. patent for ALPHA-1062 in brain injury

Apr 1, 2026, 4:30 PM EDT - 5 months ago

Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury

Apr 1, 2026, 9:51 AM EDT - 5 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Alpha Cognition Slides: Corporate presentation

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Alpha Cognition Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Alpha Cognition Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Alpha Cognition Earnings release: Q4 2025

Mar 26, 2026, 4:01 PM EDT - 5 months ago

Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

Mar 13, 2026, 1:46 PM EDT - 6 months ago

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Mar 10, 2026, 8:30 AM EDT - 6 months ago

Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences

Feb 25, 2026, 8:30 AM EST - 6 months ago

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Feb 18, 2026, 8:30 AM EST - 6 months ago

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens

Jan 7, 2026, 4:30 PM EST - 8 months ago

Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution

Dec 2, 2025, 12:00 PM EST - 9 months ago

Alpha Cognition Transcript: Fireside Chat

Dec 1, 2025, 5:51 PM EST - 9 months ago

Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners

Nov 14, 2025, 9:46 AM EST - 10 months ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Alpha Cognition Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Alpha Cognition Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Alpha Cognition Quarterly report: Q3 2025

Nov 13, 2025, 4:00 PM EST - 10 months ago

Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 12, 2025, 6:00 PM EST - 10 months ago

Alpha Cognition Slides: Corporate Presentation

Oct 30, 2025, 8:30 AM EDT - 10 months ago

Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025

Oct 14, 2025, 4:30 PM EDT - 11 months ago

Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings

Oct 8, 2025, 8:30 AM EDT - 11 months ago

Alpha Cognition Transcript: Noble Capital Markets Emerging Growth Virtual Investor Conference

Oct 6, 2025, 8:30 AM EDT - 11 months ago

Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

Sep 30, 2025, 11:14 PM EDT - 11 months ago

Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares

Sep 30, 2025, 4:58 PM EDT - 11 months ago

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Aug 28, 2025, 1:00 PM EDT - 1 year ago

Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences

Aug 22, 2025, 8:00 AM EDT - 1 year ago

Alpha Cognition Registration statement: Registration Filing

Aug 15, 2025, 5:10 PM EDT - 1 year ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update

Aug 4, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease

Jul 21, 2025, 8:00 AM EDT - 1 year ago

Alpha Cognition Registration statement: Registration Filing

Jul 15, 2025, 6:00 PM EDT - 1 year ago

Alpha Cognition Slides: Investor Presentation

Jul 8, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer's Association International Conference

Jul 1, 2025, 5:05 PM EDT - 1 year ago

Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

Jul 1, 2025, 8:00 AM EDT - 1 year ago

Alpha Cognition Registration statement: Registration Filing

May 19, 2025, 10:25 AM EDT - 1 year ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Earnings release: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview

May 6, 2025, 8:00 AM EDT - 1 year ago

Alpha Cognition Proxy statement: Proxy Filing

May 6, 2025, 8:00 AM EDT - 1 year ago

Alpha Cognition Proxy statement: Proxy Filing

May 1, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Alpha Cognition Proxy statement: Proxy Filing

Apr 30, 2025, 7:30 AM EDT - 1 year ago

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference

Apr 10, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

Apr 1, 2025, 4:27 PM EDT - 1 year ago

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition Annual report: Q4 2024

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Alpha Cognition Slides: Corporate Presentation

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease

Feb 12, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease

Jan 30, 2025, 11:05 AM EST - 1 year ago

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Jan 28, 2025, 4:00 PM EST - 1 year ago

Alpha Cognition Transcript: Investor Update

Jan 28, 2025, 4:00 PM EST - 1 year ago

Alpha Cognition Slides: Investor Update

Jan 14, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

Jan 10, 2025, 7:00 AM EST - 1 year ago

Alpha Cognition Registration statement: Registration Filing

Jan 8, 2025, 8:30 AM EST - 1 year ago

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer's Disease, in China

Squicc Sep. 11 at 5:00 PM

$ACOG

0 · Reply

FlowerInTheCellar Sep. 10 at 7:29 PM

0 · Reply

jheerdink Sep. 7 at 7:32 PM

1 · Reply

FlowerInTheCellar Sep. 1 at 9:08 PM

0 · Reply

Itinerant Sep. 1 at 4:40 PM

$ACOG Does anyone have access to the ACOG scripts weekly?

1 · Reply

Itinerant Aug. 29 at 4:25 PM

2 · Reply

Itinerant Aug. 27 at 4:05 PM

$ACOG Curiously, does someone know what exactly the label says?

1 · Reply

endrow Aug. 24 at 7:28 PM

$ACOG https://www.marketbeat.com/instant-alerts/alpha-cognition-nasdaqacog-director-purchases-10000-shares-2026-08-24/

0 · Reply

History101 Aug. 24 at 3:24 AM

$ACOG 406 watching Sun 8/23/2026

0 · Reply

GeorgeJonesFan_In_Boston Aug. 22 at 3:29 PM

$ACOG Schwab still won’t let you buy online, only through phone calls. It’s been months.

1 · Reply

dixiebull Aug. 21 at 9:39 PM

$ACOG hits 10.10, stop under 6.50 now

0 · Reply

endrow Aug. 20 at 5:12 PM

$ACOG Slowly but surely this company is starting to get the attention it deserves. In my opinion ACOG will be worth over a billion dollars by this time next year.

0 · Reply

Squicc Aug. 20 at 11:58 AM

$ACOG

0 · Reply

BIGDADDYBENZ300 Aug. 19 at 8:02 PM

$ACOG 200m market share is crazy. That drug will sell for 1-3B.

1 · Reply

Bioinvester001 Aug. 18 at 4:58 PM

$ACOG Adding, as this stock could see more big block trades. I think the institutions are starting to seriously look at this company, as the revenue stream is accelerating.

0 · Reply

FlowerInTheCellar Aug. 17 at 8:34 PM

$ACOG https://www.newsfilecorp.com/release/309918 - Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26

0 · Reply

focafoca99 Aug. 17 at 2:57 PM

$ACOG grows 2Q26 product revenue 71% to $6.0M as demand accelerates.

0 · Reply

LSOTradingDesk Aug. 16 at 11:01 AM

$ACOG 👀 watching but want to wait till the after earnings "glow" wears off we'll take closer look Wednesday and Thursday 🤔😁💰🦎

0 · Reply

endrow Aug. 14 at 4:25 PM

$ACOG This is a generational wealth making opportunity. Almost unbelievable that people are still missing this. The best oral Alzheimers drug on the market and the company is sitting at a $200 million valuation.

0 · Reply

StocktwitsEarnings Aug. 13 at 10:13 PM

$ACOG Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.40 up 51.22% YoY • Reported revenue of $6.09M up 267.56% YoY

0 · Reply

JackCampbell Aug. 13 at 9:32 PM

$ACOG thank you mgmnt team for the exceptional work this quarter!

0 · Reply

Shawshank_book_keeper Aug. 13 at 9:02 PM

$ACOG

0 · Reply

Market Cap	193.82M
Revenue (ttm)	10.22M
Net Income (ttm)	-20.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-202.25%
Debt to Equity Ratio	0.00

Volume	85,300
Avg Vol	123,798
Day's Range	N/A - N/A
Shares Out	21.78M
Stochastic %K	23%
Beta	2.32
Analysts	Strong Sell
Price Target	$18.00